Ensemble Therapeutics showcases data on new drug discovery platform at ACS National Meeting

Aug 24 2010

Ensemble Therapeutics announced today the presentation of data on its macrocyclic-based drug discovery platform at the American Chemical Society (ACS) National Meeting August 22-26, in Boston at the Boston Convention and Exposition Center.

“With their unique macrocyclic structure, Ensemblins are a new class of orally-active drugs with unique properties for binding to a large number of historically challenging human disease targets.”

Poster Presentations:

• #222: Tuesday, August 24, 2010, 5:30 p.m., "The Rapid Creation and Selection of Macrocyclic Libraries for the Modulation of Protein-Protein Interactions", Connors, et.al, Exhibit Hall C.
• #667: Tuesday, August 24, 2010, 8:00 p.m., Division of Organic Chemistry, "The Rapid Creation and Screening of Peptidic-Macrocyclic Libraries against Protein-Protein Interactions", Yan, et.al., Exhibit Hall C.
• #429: Wednesday, August 25, 2010, 7:00 p.m., Division of Medicinal Chemistry, "Drug-Like Properties Of Macrocyclic Molecules Derived From DNA-Programmed Combinatorial Libraries", Seigal, et.al, Ballroom.

Special Oral Presentation:

• #62: Young Investigators Symposium, Sunday, August 22, 2010, 9:15 a.m.
  "DNA-Programmed Chemistry Approaches to Macrocyclic Lead Compounds", Fraley, et.al, Room 205A/B. This symposium highlights up-and-coming investigators who have demonstrated outstanding promise for future contributions to organic chemistry.

"The body of data presented at ACS this year demonstrates Ensemble's progress in deploying our proprietary DNA-programmed drug discovery platform to assess large numbers of macrocycles with the goal of rapidly optimizing lead drug candidates for development of novel macrocycle-based therapeutics," said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics. "With their unique macrocyclic structure, Ensemblins are a new class of orally-active drugs with unique properties for binding to a large number of historically challenging human disease targets."